<PubmedArticle>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">20710042</PMID>
<DateCompleted>
<Year>2010</Year>
<Month>11</Month>
<Day>10</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1538-7445</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>70</Volume>
<Issue>16</Issue>
<PubDate>
<Year>2010</Year>
<Month>Aug</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>Cancer research</Title>
<ISOAbbreviation>Cancer Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>Type 1 insulin-like growth factor receptor translocates to the nucleus of human tumor cells.</ArticleTitle>
<Pagination>
<MedlinePgn>6412-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1158/0008-5472.CAN-10-0052</ELocationID>
<Abstract>
<AbstractText>The type 1 insulin-like growth factor receptor (IGF-1R) is a transmembrane glycoprotein composed of two extracellular alpha subunits and two beta subunits with tyrosine kinase activity. The IGF-1R is frequently upregulated in cancers and signals from the cell surface to promote proliferation and cell survival. Recent attention has focused on the IGF-1R as a target for cancer treatment. Here, we report that the nuclei of human tumor cells contain IGF-1R, detectable using multiple antibodies to alpha- and beta-subunit domains. Cell-surface IGF-1R translocates to the nucleus following clathrin-mediated endocytosis, regulated by IGF levels. The IGF-1R is unusual among transmembrane receptors that undergo nuclear import, in that both alpha and beta subunits traffic to the nucleus. Nuclear IGF-1R is phosphorylated in response to ligand and undergoes IGF-induced interaction with chromatin, suggesting direct engagement in transcriptional regulation. The IGF dependence of these phenomena indicates a requirement for the receptor kinase, and indeed, IGF-1R nuclear import and chromatin binding can be blocked by a novel IGF-1R kinase inhibitor. Nuclear IGF-1R is detectable in primary renal cancer cells, formalin-fixed tumors, preinvasive lesions in the breast, and nonmalignant tissues characterized by a high proliferation rate. In clear cell renal cancer, nuclear IGF-1R is associated with adverse prognosis. Our findings suggest that IGF-1R nuclear import has biological significance, may contribute directly to IGF-1R function, and may influence the efficacy of IGF-1R inhibitory drugs.</AbstractText>
<CopyrightInformation>(c)2010 AACR.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Aleksic</LastName>
<ForeName>Tamara</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Cellular Pathology, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chitnis</LastName>
<ForeName>Meenali M</ForeName>
<Initials>MM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Perestenko</LastName>
<ForeName>Olga V</ForeName>
<Initials>OV</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gao</LastName>
<ForeName>Shan</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Thomas</LastName>
<ForeName>Peter H</ForeName>
<Initials>PH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Turner</LastName>
<ForeName>Gareth D</ForeName>
<Initials>GD</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Protheroe</LastName>
<ForeName>Andrew S</ForeName>
<Initials>AS</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Howarth</LastName>
<ForeName>Mark</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Macaulay</LastName>
<ForeName>Valentine M</ForeName>
<Initials>VM</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>A6293</GrantID>
<Agency>Cancer Research UK</Agency>
<Country>United Kingdom</Country>
</Grant>
<Grant>
<GrantID>G0601061</GrantID>
<Agency>Medical Research Council</Agency>
<Country>United Kingdom</Country>
</Grant>
<Grant>
<GrantID>G0601061(79788)</GrantID>
<Agency>Medical Research Council</Agency>
<Country>United Kingdom</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Cancer Res</MedlineTA>
<NlmUniqueID>2984705R</NlmUniqueID>
<ISSNLinking>0008-5472</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D017526">Receptor, IGF Type 1</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016475">3T3 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001943">Breast Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002292">Carcinoma, Renal Cell</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002462">Cell Membrane</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002467">Cell Nucleus</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007150">Immunohistochemistry</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007680">Kidney Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011471">Prostatic Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017434">Protein Structure, Tertiary</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017526">Receptor, IGF Type 1</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">UKMS31239</OtherID>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="entrez">
<Year>2010</Year>
<Month>8</Month>
<Day>17</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2010</Year>
<Month>8</Month>
<Day>17</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2010</Year>
<Month>11</Month>
<Day>11</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">20710042</ArticleId>
<ArticleId IdType="pii">70/16/6412</ArticleId>
<ArticleId IdType="doi">10.1158/0008-5472.CAN-10-0052</ArticleId>
<ArticleId IdType="pmc">PMC2981028</ArticleId>
<ArticleId IdType="mid">UKMS31239</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>Mol Cancer Ther. 2009 Jun;8(6):1448-59</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19509240</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nat Struct Mol Biol. 2007 Nov;14(11):1049-55</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17984967</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nat Cell Biol. 2001 Sep;3(9):802-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11533659</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Oncogene. 2007 Oct 4;26(45):6499-508</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17486080</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell. 2006 Oct 6;127(1):185-97</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17018285</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Biol Chem. 2007 Aug 3;282(31):22513-24</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17545147</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Biochem Biophys Res Commun. 2007 Jul 13;358(4):1136-41</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17524361</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Cell Biol. 2003 May;23(9):3363-72</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12697834</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Proc Natl Acad Sci U S A. 2009 Feb 17;106(7):2359-64</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19174523</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Cancer Res. 2008 Oct 15;14(20):6364-70</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18927274</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Sci Signal. 2010;3(108):ra10</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20145208</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Cell Biochem. 2006 Aug 15;98(6):1570-83</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16552725</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Res. 2008 Jul 15;68(14):5669-77</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18632619</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Biol Cell. 2007 Mar;18(3):1064-72</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17215517</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Urol. 2003 Aug;170(2 Pt 1):420-4</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12853790</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>EMBO J. 2009 Sep 2;28(17):2541-53</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19680228</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Cell Endocrinol. 1996 Apr 19;118(1-2):1-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8735585</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Oncogene. 2008 Jan 10;27(3):397-403</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17700539</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nat Rev Cancer. 2006 May;6(5):403-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16612404</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Mol Life Sci. 2000 Jul;57(7):1050-93</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10961344</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Res. 2002 May 15;62(10):2942-50</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12019176</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Res. 2003 Feb 1;63(3):627-35</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12566306</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Commun Signal. 2008 Oct 24;6:8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18950493</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>BJU Int. 2011 May;107(9):1488-99</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20840329</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>